BMS cuts $3.15bn deal with Century for cancer cell therapiesBristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP Share XBMS cuts $3.15bn deal with Century for cancer cell therapieshttps://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/
ASH abstract drop backs Roche’s Polivy in first-line lymphomaRoche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and Share XASH abstract drop backs Roche’s Polivy in first-line lymphomahttps://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/
Joy as sickle cell patients get access to Novartis’ Adakveo after NICE rulingPeople living with sickle cell disease (SCD) in England and Wales will be able to get access to Share XJoy as sickle cell patients get access to Novartis’ Adakveo after NICE rulinghttps://pharmaphorum.com/news/joy-as-sickle-cell-patients-get-access-to-novartis-adakveo-after-nice-ruling/
Gamble by Takeda on unproven cancer mechanism draws a blankTakeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – Share XGamble by Takeda on unproven cancer mechanism draws a blankhttps://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/
After FDA snub, EMA backs FibroGen, Astellas’ roxadustatThe EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease Share XAfter FDA snub, EMA backs FibroGen, Astellas’ roxadustathttps://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLRoche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed Share XArmed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLhttps://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionSanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) Share XEHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionhttps://pharmaphorum.com/news/eha21-sanofi-builds-case-for-rare-disease-drug-sutimlimab-after-fda-rejection/
BMS will file for earlier-line use of Breyanzi in lymphoma after trial winBristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but Share XBMS will file for earlier-line use of Breyanzi in lymphoma after trial winhttps://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/
